These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2837240)
1. Topoisomerases: novel therapeutic targets in cancer chemotherapy. Hsiang YH; Wu HY; Liu LF Biochem Pharmacol; 1988 May; 37(9):1801-2. PubMed ID: 2837240 [No Abstract] [Full Text] [Related]
2. DNA topoisomerases as targets for chemotherapy. Rose KM FASEB J; 1988 Jun; 2(9):2474-8. PubMed ID: 2836254 [TBL] [Abstract][Full Text] [Related]
3. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Capranico G; Binaschi M Biochim Biophys Acta; 1998 Oct; 1400(1-3):185-94. PubMed ID: 9748568 [TBL] [Abstract][Full Text] [Related]
4. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Pommier Y; Leteurtre F; Fesen MR; Fujimori A; Bertrand R; Solary E; Kohlhagen G; Kohn KW Cancer Invest; 1994; 12(5):530-42. PubMed ID: 7922710 [No Abstract] [Full Text] [Related]
5. DNA topoisomerases in chemotherapy. Kaufmann S Cancer Cells; 1991 Jan; 3(1):24-7. PubMed ID: 1851030 [No Abstract] [Full Text] [Related]
6. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421 [TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941 [TBL] [Abstract][Full Text] [Related]
8. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Thielmann HW; Popanda O; Gersbach H; Gilberg F Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865 [TBL] [Abstract][Full Text] [Related]
9. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Gatto B; Capranico G; Palumbo M Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890 [TBL] [Abstract][Full Text] [Related]
10. Curcumin as a DNA topoisomerase II poison. Martín-Cordero C; López-Lázaro M; Gálvez M; Ayuso MJ J Enzyme Inhib Med Chem; 2003 Dec; 18(6):505-9. PubMed ID: 15008515 [TBL] [Abstract][Full Text] [Related]
11. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Solary E; Bertrand R; Pommier Y Leuk Lymphoma; 1994 Sep; 15(1-2):21-32. PubMed ID: 7858500 [TBL] [Abstract][Full Text] [Related]
12. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. Pourpak A; Landowski TH; Dorr RT J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106 [TBL] [Abstract][Full Text] [Related]
13. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479 [TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance associated with altered topoisomerase II activity--topoisomerases II as targets for rational drug design. Morrow CS; Cowan KH J Natl Cancer Inst; 1990 Apr; 82(8):638-9. PubMed ID: 2157026 [No Abstract] [Full Text] [Related]
15. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Nitiss JL Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029 [TBL] [Abstract][Full Text] [Related]
16. From DNA damage to G2 arrest: the many roles of topoisomerase II. Larsen AK; Escargueil AE; Skladanowski A Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724 [TBL] [Abstract][Full Text] [Related]
17. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Gewirtz DA Biochem Pharmacol; 1991 Nov; 42(12):2253-8. PubMed ID: 1662508 [No Abstract] [Full Text] [Related]
18. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of aroylthiourea derivatives of 4-β-amino-4'-O-demethyl-4-desoxypodophyllotoxin as novel topoisomerase II inhibitors. Zhao Y; Ge CW; Wu ZH; Wang CN; Fang JH; Zhu L Eur J Med Chem; 2011 Mar; 46(3):901-6. PubMed ID: 21277655 [TBL] [Abstract][Full Text] [Related]
20. [Poisons of DNA topoisomerases I and II]. Charcosset JY; Soues S; Laval F Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]